Sigma Planning Corp’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-12,729
Closed -$59.4K 1232
2024
Q2
$59.4K Sell
12,729
-561
-4% -$3.17K ﹤0.01% 1153
2024
Q1
$98.6K Buy
+13,290
New +$110K ﹤0.01% 1180
2023
Q4
Sell
-14,558
Closed -$114K 932
2023
Q3
$114K Sell
14,558
-409
-3% -$3.51K ﹤0.01% 1134
2023
Q2
$123K Buy
14,967
+397
+3% +$3.46K ﹤0.01% 1140
2023
Q1
$106K Buy
14,570
+1,866
+15% +$16.6K ﹤0.01% 1234
2022
Q4
$113K Sell
12,704
-3,911
-24% -$42.9K ﹤0.01% 1186
2022
Q3
$203K Sell
16,615
-444
-3% -$6.92K 0.01% 1118
2022
Q2
$202K Buy
17,059
+2,187
+15% +$29.3K 0.01% 1155
2022
Q1
$283K Buy
14,872
+3,484
+31% +$64.8K 0.01% 1084
2021
Q4
$302K Buy
11,388
+383
+3% +$13.2K 0.01% 1072
2021
Q3
$452K Buy
11,005
+3,944
+56% +$216K 0.01% 865
2021
Q2
$400K Buy
+7,061
New +$261K 0.01% 928
2021
Q1
Sell
-4,038
Closed -$283K 1352
2020
Q4
$283K Buy
+4,038
New +$166K 0.01% 928
2018
Q3
Sell
-6,507
Closed -$233K 963
2018
Q2
$233K Sell
6,507
-43
-0.7% -$1.52K 0.02% 762
2018
Q1
$217K Buy
+6,550
New +$233K 0.02% 742

Other funds holding EDIT

Sigma Planning Corp's EDIT Position: Q3 2024 in Review

Sigma Planning Corp sold out of Editas Medicine (EDIT) in Q3 2024, closing a stake of 12,729 shares — an estimated $59.4K sold.

Sigma Planning Corp first reported a position in EDIT in Q1 2018 and held it in 15 quarters. The position peaked at $452K in Q3 2021. 229 funds tracked by Wall St. Rank hold EDIT as of Q3 2024.

  • Sigma Planning Corp reported no remaining Editas Medicine position as of Q3 2024 after selling out during the quarter.
  • Sigma Planning Corp sold 12,729 Editas Medicine shares in Q3 2024, an estimated $59.4K.
  • Sigma Planning Corp first reported a position in Editas Medicine in Q1 2018 and held it in 15 quarters.
  • Sigma Planning Corp's Editas Medicine position peaked at $452K in Q3 2021.
  • 229 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2024.

Based on Sigma Planning Corp's 13F filing for Q3 2024, filed 4 Nov 2024.